Foldax LifePolymer and A Novel Polymeric Heart Valve: Pathway to Clinical Evaluation
Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery · 2025
DOI: 10.1177/15569845251375566 ↗Kurz gefasst
Fallbericht in der Zeitschrift Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2025. Verfasst von Andy C Kiser und 5 weiteren Autor:innen. Beteiligte Einrichtung: St. Clair Cardiovascular Surgical Associates, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Polymers, Heart Valve Prosthesis Implantation, Mitral Valve. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Objective
An optimal valve replacement prosthesis demands durable leaflet technology, superior hemodynamic performance, and ease of use. Preclinical evaluation of polymer leaflets has historically demonstrated mechanical failure related to biodegradation. We present the preclinical evaluation of the novel TRIA™ polymer valve (Foldax, Salt Lake City, UT, USA) and a case report of TRIA mitral valve replacement.
Methods
A uniquely formulated, biostable, and biocompatible polymer (LifePolymer™ [LP], Foldax) has been designed to meet the functional demands of cardiac hemodynamics. Preclinical in vitro evaluation included biocompatibility testing, thrombogenicity testing, and toxicologic assessment followed by evaluation in the arteriovenous shunt of nonhuman primates and in the aortic position in sheep. Clinical evaluation of early human aortic and mitral implantation included computed tomography imaging and echocardiographic examination.
Results
In vitro studies of LP demonstrated no evidence of toxicity or tissue injury, no cytological injury in cell culture, and no intracutaneous sensitization. LP proved to be nonhemolytic by direct and extract methods, and complement activation was insignificant. Genotoxicity analysis proved LP to be nonmutagenic. All standard toxicologic assessments were within the margin of safety. Biostability was confirmed without polymer degradation or excessive comparative thrombogenicity. Ovine 6-month aortic valve explantation showed no leaflet calcification and minimal fibrinous depositions. An early human case example shows no evidence of leaflet thrombus formation at 6 months and a mean mitral gradient of 3 mm Hg at 12 months.
Conclusions
LP has met the requirements for a prosthetic polymer human heart valve. The surgical TRIA Mitral Valve has demonstrated promising early human clinical success, potentially facilitating a lifetime valve replacement strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. Clair Cardiovascular Surgical Associates, Pittsburgh, PA, USA.
- New York Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY, USA.
- Intermountain Heart Institute, Salt Lake City, UT, USA.
- Riverside Methodist Hospital, OhioHealth, Columbus, OH, USA.
ORCID-Profile: Andy C Kiser
Zitieren
APA
Kiser, A. C., George, I., Wilson, B. D., Whisenant, B., Yakubov, S. J., & Leon, M. B. (2025). Foldax LifePolymer and A Novel Polymeric Heart Valve: Pathway to Clinical Evaluation. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. https://doi.org/10.1177/15569845251375566
Vancouver
Kiser AC, George I, Wilson BD, Whisenant B, Yakubov SJ, Leon MB. Foldax LifePolymer and A Novel Polymeric Heart Valve: Pathway to Clinical Evaluation. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2025. doi:10.1177/15569845251375566
BibTeX
@article{Kiser2025,
author = {Kiser, Andy C and George, Isaac and Wilson, Brent D and Whisenant, Brian and Yakubov, Steven J and Leon, Martin B},
title = {Foldax LifePolymer and A Novel Polymeric Heart Valve: Pathway to Clinical Evaluation},
journal = {Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery},
year = {2025},
doi = {10.1177/15569845251375566}
}
EUVIMED